Similar articles

• The appropriate role of cost-effectiveness in determining device coverage: a case study of drug-eluting stents.

  Firth BG, Cooper LM, Fearn S. Firth BG, et al. Health Aff (Millwood). 2008 Nov-Dec;27(6):1577-86. doi: 10.1377/hlthaff.27.6.1577. Health Aff (Millwood). 2008. PMID: 18997214
• Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data.

  Bischof M, Briel M, Bucher HC, Nordmann A. Bischof M, et al. Value Health. 2009 Jul-Aug;12(5):649-56. doi: 10.1111/j.1524-4733.2009.00513.x. Value Health. 2009. PMID: 19490551
• Diffusion of new technology and payment policies: coronary stents.

  Shih C, Berliner E. Shih C, et al. Health Aff (Millwood). 2008 Nov-Dec;27(6):1566-76. doi: 10.1377/hlthaff.27.6.1566. Health Aff (Millwood). 2008. PMID: 18997213
• Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.

  Health Quality Ontario. Health Quality Ontario. Ont Health Technol Assess Ser. 2015 Nov 1;15(20):1-62. eCollection 2015. Ont Health Technol Assess Ser. 2015. PMID: 26719778 Free PMC article. Review.
• Drug-eluting coronary-artery stents.

  Stefanini GG, Holmes DR Jr. Stefanini GG, et al. N Engl J Med. 2013 Jan 17;368(3):254-65. doi: 10.1056/NEJMra1210816. N Engl J Med. 2013. PMID: 23323902 Review. No abstract available.